Dermatology, Hospital Vall d'Hebron, Barcelona, Spain
Universitat Autònoma de Barcelona, Barcelona, Spain.
BMJ Case Rep. 2021 Jan 28;14(1):e237310. doi: 10.1136/bcr-2020-237310.
Drug-induced sarcoidosis-like reactions (DISRs) are systemic granulomatous diseases that develop in the context of a new drug onset. Ipilimumab is an immune checkpoint inhibitor (ICI) approved for the treatment of advanced melanoma which has been associated with DISR. Differential diagnosis between tumour progression and DISR by positron emission tomography/computed tomography (PET/CT) in patients treated with an ICI can be a challenge. A 31-year-old woman was diagnosed with a stage IIIB melanoma in her back. Ipilimumab 10 mg/kg was initiated. After 1 month of finishing the treatment a routine, PET/CT showed multiple enlarged mediastinal and hilar lymph nodes FDG-positive. A transbronchial biopsy showed sarcoid-like granulomatous infiltration which favoured the diagnosis of DISR related to ipilimumab. The patient remained asymptomatic and lymphadenopathy regressed progressively after 11 months. Our work highlights the importance of differentiating DISR from tumour progression, before unnecessary changes in therapeutic strategies. PET/CT is a useful diagnostic tool for its follow-up.
药物诱导的类肉瘤样反应(DISR)是一种全身性肉芽肿性疾病,在新药物开始使用的情况下发生。易普利姆玛(Ipilimumab)是一种免疫检查点抑制剂(ICI),已被批准用于治疗晚期黑色素瘤,它与 DISR 有关。在接受 ICI 治疗的患者中,通过正电子发射断层扫描/计算机断层扫描(PET/CT)鉴别肿瘤进展和 DISR 可能具有挑战性。一名 31 岁女性被诊断为背部 IIIB 期黑色素瘤。开始给予易普利姆玛 10 mg/kg。治疗结束后 1 个月,常规 PET/CT 显示多个纵隔和肺门增大的淋巴结 FDG 阳性。经支气管活检显示类肉瘤样肉芽肿性浸润,这支持与易普利姆玛相关的 DISR 诊断。患者无症状,淋巴结病在 11 个月后逐渐消退。我们的工作强调了在不必要改变治疗策略之前,区分 DISR 与肿瘤进展的重要性。PET/CT 是一种有用的随访诊断工具。